These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38828373)

  • 21. Multicenter Genomic Analysis of Carbapenem-Resistant Klebsiella pneumoniae from Bacteremia in China.
    Cienfuegos-Gallet AV; Zhou Y; Ai W; Kreiswirth BN; Yu F; Chen L
    Microbiol Spectr; 2022 Apr; 10(2):e0229021. PubMed ID: 35230130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant
    Zhen S; Zhao Y; Chen Z; Zhang T; Wang J; Jiang E; Zhang F; Mi Y; Zhu X; Han M; Xiao Z; Wang J; Feng S
    Front Cell Infect Microbiol; 2023; 13():1156651. PubMed ID: 37415825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
    Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
    J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
    Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
    Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Wang SS; Lee NY; Hsueh PR; Huang WH; Tsui KC; Lee HC; Wu CJ; Chang CM; Huang CC; Huang CF; Ko WC
    J Microbiol Immunol Infect; 2011 Aug; 44(4):282-8. PubMed ID: 21524962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Chopra T; Marchaim D; Veltman J; Johnson P; Zhao JJ; Tansek R; Hatahet D; Chaudhry K; Pogue JM; Rahbar H; Chen TY; Truong T; Rodriguez V; Ellsworth J; Bernabela L; Bhargava A; Yousuf A; Alangaden G; Kaye KS
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3936-42. PubMed ID: 22547616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options.
    Zhang L; Zhen S; Shen Y; Zhang T; Wang J; Li J; Lin Q; Xiao Z; Zheng Y; Jiang E; Han M; Wang J; Feng S
    Ann Clin Microbiol Antimicrob; 2023 May; 22(1):41. PubMed ID: 37202758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of nomograms for predicting the risk probability of carbapenem resistance and 28-day all-cause mortality in gram-negative bacteremia among patients with hematological diseases.
    Jian X; Du S; Zhou X; Xu Z; Wang K; Dong X; Hu J; Wang H
    Front Cell Infect Microbiol; 2022; 12():969117. PubMed ID: 36683699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk Factors of 30-Day All-Cause Mortality in Patients with Carbapenem-Resistant
    Liu KS; Tong YS; Lee MT; Lin HY; Lu MC
    J Pers Med; 2021 Jun; 11(7):. PubMed ID: 34209780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance.
    Amanati A; Sajedianfard S; Khajeh S; Ghasempour S; Mehrangiz S; Nematolahi S; Shahhosein Z
    BMC Infect Dis; 2021 Jul; 21(1):636. PubMed ID: 34215207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteraemia in children: a retrospective study.
    Meng H; Yang J; Niu M; Zhu H; Zhou Y; Lu J
    Int J Antimicrob Agents; 2023 Oct; 62(4):106933. PubMed ID: 37500022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
    Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
    Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
    Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From Epidemiology of Community-Onset Bloodstream Infections to the Development of Empirical Antimicrobial Treatment-Decision Algorithm in a Region with High Burden of Antimicrobial Resistance.
    Chotiprasitsakul D; Trirattanapikul A; Namsiripongpun W; Chaihongsa N; Santanirand P
    Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
    Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
    J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial resistance trends in bloodstream infections at a large teaching hospital in China: a 20-year surveillance study (1998-2017).
    Tian L; Zhang Z; Sun Z
    Antimicrob Resist Infect Control; 2019; 8():86. PubMed ID: 31161033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and factors associated with carbapenem-resistant Enterobacterales (CRE) infection among hematological malignancies patients with CRE intestinal colonization.
    Chen X; Wen X; Jiang Z; Yan Q
    Ann Clin Microbiol Antimicrob; 2023 Jan; 22(1):3. PubMed ID: 36627626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics, Outcomes, and Clinical Indicators of Bloodstream Infections in Neutropenic Patients with Hematological Malignancies: A 7-Year Retrospective Study.
    Wang S; Song Y; Shi N; Yin D; Kang J; Cai W; Duan J
    Infect Drug Resist; 2023; 16():4471-4487. PubMed ID: 37449245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
    Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.